| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.26▼ | 1.26▼ | 1.27▼ | 1.30▼ | 1.26▲ |
| MA10 | 1.26▼ | 1.26▼ | 1.27▼ | 1.29▼ | 1.26▲ |
| MA20 | 1.26▼ | 1.27▼ | 1.28▼ | 1.26▲ | 1.36▼ |
| MA50 | 1.27▼ | 1.30▼ | 1.32▼ | 1.25▲ | N/A |
| MA100 | 1.28▼ | 1.32▼ | 1.27▼ | 1.38▼ | N/A |
| MA200 | 1.32▼ | 1.26▼ | 1.25▲ | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.000▲ | 0.002▲ | -0.001▼ | 0.005▲ | 0.163▲ |
| RSI | 45.054▼ | 44.994▼ | 43.035▼ | 49.664▼ | 25.014▼ |
| STOCH | 63.333 | 49.537 | 58.333 | 50.028 | 49.729 |
| WILL %R | -60.000 | -50.000 | -50.000 | -67.742 | -50.000 |
| CCI | -43.750 | -21.212 | -58.083 | -15.945 | 60.984 |
|
Thursday, June 12, 2025 09:00 AM
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the ...
|
|
Tuesday, June 03, 2025 12:59 PM
Explore the NASDAQ:CLYM financials. Find the Climb Bio financial statements for a comprehensive overview of the company’s financial health. This summary highlights critical numbers from key ...
|
|
Sunday, June 01, 2025 05:00 PM
The firm increased its portfolio allocation in CLYM by 30.08% over the last quarter ... the author and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of financial ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 13/06/25 | 1.24 | 1.30 | 1.21 | 1.26 | 168,400 |
| 12/06/25 | 1.26 | 1.30 | 1.211 | 1.28 | 135,700 |
| 11/06/25 | 1.36 | 1.37 | 1.26 | 1.26 | 196,000 |
| 10/06/25 | 1.31 | 1.39 | 1.31 | 1.375 | 158,323 |
| 09/06/25 | 1.41 | 1.45 | 1.31 | 1.34 | 252,864 |
| 06/06/25 | 1.40 | 1.47 | 1.27 | 1.39 | 1,003,500 |
| 05/06/25 | 1.30 | 1.30 | 1.22 | 1.24 | 70,360 |
| 04/06/25 | 1.30 | 1.36 | 1.28 | 1.29 | 77,675 |
| 03/06/25 | 1.18 | 1.30 | 1.18 | 1.29 | 176,343 |
| 02/06/25 | 1.18 | 1.22 | 1.16 | 1.18 | 113,477 |
|
|
||||
|
|
||||
|
|